Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Cancer Treat Rev. 2013 Mar 1;39(7):10.1016/j.ctrv.2013.01.008. doi: 10.1016/j.ctrv.2013.01.008

Figure 5.

Figure 5

RTOG Grade ≥2 GI toxicity vs. follow-up time of CFRT vs. HFRT RCTs benchmarked to high-dose RT arm of escalation RCTs for prostate cancer

The y-axis shows incidence of late RTOG Grade ≥2 toxicity (%), and the x-axis shows the follow-up time in years. Individual arms of phase III randomized controlled trials (RCTs) comparing conventionally fractionated radiotherapy (CFRT) and hypofractionated radiation therapy (HFRT) are shown on the plot with first author and year of publication. As a benchmark for these studies, the higher-dose arms of dose escalation RCTs are shown on the plot with first author and year of publication. Black squares (∎) refer to the GI toxicity rates of CFRT arms. Black triangles (▴) refer to the GI toxicity rates of HFRT arms. Gray circles (●) refer to the GI toxicity rates of the higher dose arm of dose escalation studies. The individual RT schedule of an arm is shown near each data point: total dose, number of fractions, and Gy/fraction.